
Explore Cerebion Modulation in Multiple Myeloma Based on In Vitro Studies¹⁻⁵




IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.



Role of Oncogenes in Myeloma Cell Activity

Based on In Vitro Studies



ligase complex

protein degradation6

Initiates ubiquitin-mediated

Transcription factors



Add CELMoD® Agents

Cytoplasm

Nucleus

+ IRF4 + c-MYC



Upregulation of oncogenes IRF4 and c-MYC in myeloma cells promotes myeloma cell proliferation¹³

Proteasome

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

> IMiD® and CELMoD® are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company. © 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21

Bristol Myers Squibb



Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies



with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


Bristol Myers Squibb

IMID® and CELMoD® are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company. © 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21



Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies



Bristol Myers Squibb

with novel agents such as iberdomide and CC-92480, their downstream effects differ.


The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD[®] and CELMoD[®] are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21



T-Cell Activity in Multiple Myeloma

Based on In Vitro Studies



Cereblon E3 ubiquitin ligase complex

Initiates ubiquitin-mediated protein degradation6



Transcription factors





Cytoplasm

Nucleus

Ikaros and Aiolos repress IL-2 gene expression9

+ Proteasome

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


+ IL-2





Cereblon Modulation Inside a T Cell

Based on In Vitro Studies



Cereblon E3 ubiquitin ligase complex

Initiates ubiquitin-mediated protein degradation⁶





Ikaros and Aiolos are



Nucleus

Cytoplasm

Drestinies studies have demonstrated that togeting liveres

Preclinical studies have demonstrated that targeting Ikaros and Aiolos for degradation resulted in increased expression of *IL-2*. This led to an increase in the number and function of NK and T cells.^{5,10,16}

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Bristol Myers Squibb


IMiD® and CELMoD® are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.

© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21



Cereblon Modulation Inside a T Cell

Based on In Vitro Studies



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

and T cells.5,10,16



IMiD® and CELMoD® are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.

© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21